Stocktoria
Mineralys Therapeutics, Inc. MLYS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-02-10
Mineralys Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $132.0M | $168.6M | $70.4M | $26.2M |
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M |
| Income tax | $0 | — | — | — |
| Net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M |
| EPS (diluted) | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M | -$29.2M |
| Cash & equivalents | $172.9M | $114.1M | $49.3M | $87.7M |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M |
| Shareholders' equity | $646.7M | $191.3M | $241.2M | -$52.3M |
Source: SEC EDGAR filings · CIK 0001933414 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.